or the brain and autonomic information simultaneous between physician and patient. Also, last month, I visited the FDA and met with the director of the Center for Drug Evaluation and Research (Janet Woodcock) and her team. They want our Harvard program to team up with them and with the pharmaceutical industry to create a non-profit conso

or the brain and autonomic information simultaneous between physician and patient. Also, last month, I visited the FDA and met with the director of the Center for Drug Evaluation and Research (Janet Woodcock) and her team. They want our Harvard program to team up with them and with the pharmaceutical industry to create a non-profit conso

ROL NUMBER 257 - CONFIDENTIAL HOUSE_OVERSIGHT_024017 Journal of Medicine editorial (November 2013), where Janet Woodcock, MD, the FDA’s Director of the Center for Drug Evaluation and Research and other senior FDA staff members as co-authors, discussed the FDA’s new breakthrough therapy designation that can be granted to expedite the review